secwatch.observer — SEC 8-K summary
======================================

Issuer:     UroGen Pharma Ltd. (URGN)
CIK:        0001668243
Form:       8-K
Filed at:   2024-09-24T23:59:59+00:00
Accession:  0001193125-24-224801
Event type: debt
Sentiment:  neutral
Materiality: 0.50
Item codes: 2.03
LLM model:  deepseek-v4-flash:cloud@v2

UroGen Pharma draws $25M Tranche C loan under credit facility
-------------------------------------------------------------

- Received $25M third tranche loan on Sept 23, 2024; proceeds for general corporate and working capital needs.
- Interest rate: 3-month SOFR + 7.25% + 0.26161% p.a., floor 2.50%, payable quarterly.
- Matures Mar 16, 2027, extended to Mar 16, 2028 if FDA approves UGN-102 by June 30, 2025.
- Repayment in four equal quarterly installments starting June 30, 2026 (or June 30, 2027 if FDA condition met).
- Loan is secured by substantially all of the credit parties' tangible and intangible assets.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1668243/000119312524224801/0001193125-24-224801-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1668243/000119312524224801/d849854d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-24-224801

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer